Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2017-2022 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Global
Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022”

report has been added to Research and Markets’ offering.

“Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook
2022”
report gives comprehensive insight on clinical and
non-clinical parameters related to emergence and growth of CDK
inhibitors in cancer therapy.

As per report findings, CDK inhibitors have emerged as new growth
frontier for the organizations involved in the research, development,
licensing and commercialization of targeted cancer therapies. There are
2 CDK inhibitors commercially available in the market for the treatment
of cancer and more than 45 CDK inhibitors are in various phases of
clinical pipeline.

Key Topics Covered:

1. Cyclin Dependent Kinase Inhibitors -An Introduction to a
Promising Cancer Therapeutic

1.1 History of Discoveries Leading to Cyclin Dependent Kinase Inhibitor
Drug

1.2 An Insight into Cell Cycle, Cyclin & the Role of CDKs

1.3 Cyclin Dependent Kinase Inhibitors for Cancer – An Overview

2. Cyclin Dependent Kinase Pathway as Targets for Cancer Therapy

2.1 CDK Pathway & Cell Cycle Checkpoints

2.2 Role of Cyclin Dependent Kinases in Carcinogenesis

2.3 Cyclin Dependent Kinases Associated With Various Cancers

3. Selectivity & Working Mechanism of a Cancer CDKs Inhibitor

4. Types of CDK Inhibitors

4.1 ATP Competitive CDK Inhibitors

4.2 ATP Non Competitive Inhibitors

4.3 Allosteric Inhibitors

5. Recent Advances in the CDKs Related Cancer Therapy

5.1 CDK 4/6 in Breast Cancer

5.2 Role of CDKs in Hematological Malignancies

6. CDK Inhibitors as Combinational Cancer Therapeutic

7. Current Market Scenario of Cancer CDKs inhibitors

7.1 Commercial Aspects of CDKs Inhibitor

7.2 Key Market Players in the Cancer CDKs Inhibitor Market

7.3 Global Cancer CDK-Inhibitors Pipeline Overview

8. Marketed Cancer CDK Inhibitors Clinical Insight

8.1 Palbociclib (Ibrance)

8.2 Ribociclib (Kisqali)

9. Price Analysis of Cancer CDKs Inhibitors

9.1 Commercially Available CDK Inhibitors Price Analysis

9.1.1 Cost of Approved Cancer CDKs Inhibitor

9.1.2 Average Cost of CDKs Inhibitors Currently Under Research

9.2 Comparison of Cancer CDKs inhibitor to other Cancer Drugs & Therapies

10. Driving Factors of the Cancer CDKs Inhibitors Market

10.1 Accelerated Approval of Previously Introduced CDKs Inhibitor for
Breast Cancer- Ibrance

10.2 Increasing Prevalence of Cancer

10.3 Presence of a Robust Clinical Pipeline

10.4 Advancement in Research & Development

10.5 High Unmet Medical Needs

11. CDK Inhibitors Market Challenges

11.1 High Cost Factor Associated with Cancer CDKs Inhibitor

11.2 Scientific & Technical Limitations

11.3 Side Effects & unreliable Efficacy

11.4 Competition from other Cancer Therapeutic Segments

11.5 Slow FDA Approvals

11.6 Commercial Challenges

12. Anticipation Regarding the Future of CDKs Inhibitor Cancer
Therapy Market

13. Global Cancer CDK Inhibitors Clinical Trials Insight by
Company, Indication & Phase

13.1 Preclinical

13.2 Phase-I

13.3 Phase-I/II

13.4 Phase-II

13.5 Phase-III

13.6 Preregistration

14. Competitive Landscape

  • Amgen
  • Anygen
  • Astex
  • Bayer Pharmaceuticals
  • BioCAD
  • Cyclacel
  • Eli – Lilly
  • G1 Therapeutics
  • Merck
  • Nerviano Medical Science
  • Pfizer
  • Piramal Life
  • Sanofi-Aventis
  • Syros Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/research/j62z7q/global_cancer_cdk

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs